Immunotherapies Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Immunotherapies stocks.

Immunotherapies Stocks Recent News

Date Stock Title
May 15 PDSB PDS Biotechnology GAAP EPS of -$0.30 beats by $0.06
May 15 PDSB PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
May 15 RCUS Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO
May 14 NBTX NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
May 14 AFMD Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
May 14 PYXS Pyxis Oncology GAAP EPS of -$0.06, revenue of $16.1M
May 14 AFMD Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates
May 14 PYXS Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
May 12 RCUS Arcus Biosciences, Inc. (NYSE:RCUS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 11 IMCR Analysts Have Made A Financial Statement On Immunocore Holdings plc's (NASDAQ:IMCR) First-Quarter Report
May 10 RCUS Arcus Biosciences Surpasses Analyst Revenue Forecasts in Q1 2024
May 10 GNLX Genelux GAAP EPS of -$0.29 misses by $0.06
May 10 RCUS Arcus Biosciences First Quarter 2024 Earnings: Beats Expectations
May 9 PDSB PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
May 9 GNLX Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
May 9 RCUS Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2024 Earnings Call Transcript
May 9 PDSB PDS Biotech to Participate in Upcoming May 2024 Investor Conferences
May 9 PYXS Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
May 9 RCUS Arcus Biosciences Inc (RCUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
May 9 RCUS Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript
Immunotherapies

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

Browse All Tags